IMPACT THERAP-B (07630.HK): EU Approves Senaparib for Ovarian Cancer

On 17 Nov 2026, IMPACT THERAP-B (07630.HK) said the EU approved senaparib for first-line maintenance in advanced ovarian cancer, following a CHMP opinion.

NewTimeSpace News: On 17 November 2026, IMPACT Therapeutics, Inc (stock code: 7630) published an announcement under Rule 13.09 of the Listing Rules and the inside information provisions of Part XIVA of the Securities and Futures Ordinance that the European Commission has granted final approval for its self-developed drug senaparib, sold overseas as Sepalna®, for maintenance treatment of advanced epithelial ovarian, fallopian tube and primary peritoneal cancer.

The approval follows a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency. Senaparib is described as the first China-origin PARP inhibitor approved by the EU for first-line maintenance treatment across the full population of advanced ovarian cancer, marking a further step for domestic targeted cancer drugs in Europe.

Senaparib is a novel, highly active PARP1/2 inhibitor whose molecular structure provides target selectivity and a wide safety margin. Its capsules were approved by China's National Medical Products Administration in January 2025 for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who achieved a complete or partial response to platinum-based chemotherapy, and were included in the national reimbursement list in December 2025.

The Company is advancing global clinical and regulatory development, lifecycle management and combination studies, and cautioned under Rule 18A.05 that it cannot guarantee eventual marketing of the drug in licensed territories.

×
Share to WeChat

Open WeChat, use the "Scan", and share to my Moments.